Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

September 12, 2014 Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC). Luciano Rossetti, Global Head of Research & Development at Merck Serono, said: “While the data from the exploratory subgroup …

BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer

September 11, 2014 BioTime, Inc. announced that its subsidiary Asterias Biotherapeutics, Inc. has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity’s development and commercialization arm, to conduct a clinical trial of Asterias’ novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer. AST-VAC2 is a non-patient specific (allogeneic) cancer vaccine designed to stimulate patients’ immune …

Batu Biologics Strategy for FDA Approval of Lung Cancer Immunotherapy Featured in San Diego Business Journal

July 27th, 2014 Batu Biologics announced today that it’s President and CEO, Samuel C. Wagner, was featured in the weekly business publication, the San Diego Business Journal. The article, which was published in the July 21st edition, discussed the company’s strategy in developing its immunotherapeutic lung cancer vaccine, ValloVax, for which FDA Investigational New Drug (IND) submission is planned in Q1 …

EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy April 7, 2014 EMD Serono, Inc., a subsidiary of Merck KGaA, …

Potential Lung Cancer Vaccine Shows Renewed Promise

March 20, 2014 Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an …

Merck goes back to START with lung cancer vaccine

  Like a phoenix rising from the ashes, Merck Serono’s experimental lung cancer vaccine is being revived by the German firm after previously failing a late-stage clinical trial. The previous trial, known as START, failed to provide evidence that the Stimuvax cancer vaccine improved survival, but it seems that insights gleaned from the failure means the therapy isn’t yet dead. …

Lung Cancer vaccine CimaVax-EGF – CIM Cuba

At the recent World Vaccine Congress Washington in April 2012 we had the pleasure of welcoming Dr Diego Venegas Ojeda, as one of our speakers. Dr Venegas is an Oncologist and Assistant Professor of Faculty of Medicine “Alberto Hurtado” at the Universidad Peruana Cayetano Heredia, Committee Immunology Cancer of Latin American Immunology Association. Dr Venegas worked very closely with the …

Cancer vaccine trial in Singapore shows promising signs of success

A cancer vaccine suitable for lung, breast, prostate, colon and ovarian cancer has shown promising results in a vaccine trial conducted in Singapore. It was tested for the first time on four patients with Stage 4 cancer and no major side effects have been observed yet. The vaccine trial was launched by the National Cancer Centre of Singapore in September …

Batu Biologics Recruits Cancer Immunologist to Scientific Advisory Board

Collaboration of IND-enabling experiments for ValloVax™ with Dr. Fang November 19, 2014 Batu Biologics, an immunotherapy company working to develop ValloVax, an anti-angiogenic cancer vaccine, announced today the addition of Dr. Deyu Fang to its Scientific Advisory Board. Deyu Fang, Ph.D. is an immunologist and associate professor working in the Department of Pathology at Northwestern University Feinberg School of Medicine. …

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Merck’s therapeutic cancer vaccine candidate, tecemotide, has shown no treatment effect in any trial endpoints Merck’s experimental therapeutic cancer vaccine,  in partnership with Oncothyreon,  has recently shown disappointing clinical trial results after the drug failed to meet its primary endpoint, as well as several other secondary endpoints. Many pharmaceutical companies are currently developing therapeutic cancer vaccines, and these are the …